KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

Overview of attention for article published in Future Oncology, February 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 1 news outlet
policy: 1 policy source
twitter: 4 X users

patent: 1 patent
video: 1 YouTube creator
podcasts: 1 podcast

Readers on

mendeley: 164 Mendeley

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 7,922 followers.

Find out about the describe the design and rationale of the KEYNOTE-590 Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer https://t.co/WQM4KE2Juz https://t.co/2CYUtHapas

Read this recently published #freeaccess clinical trial protocol discussing the KEYNOTE-590 phase III study

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. - PubMed - NCBI https://t.co/ynqgDpmE0B #hvhebron #onco @fsgfon

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. https://t.co/GnYx0xvgVg

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.